Discover the full directors' dealings record of NUVASIVE INC, a listed equity based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, NUVASIVE INC has published 35 reports. The latest transaction was reported on 1 June 2022 — Levée d'options. Among the most active insiders: Barry James Christopher. All data is free.
25 of 35 declarations
NuVasive, Inc. was a U.S.-based medical device company focused on spine surgery and spinal care technologies. It was historically listed on the NASDAQ in the United States under the ticker NUVA. Founded in 1997, the company built its identity around minimally invasive spine surgery and procedurally integrated solutions designed to improve surgical precision, reduce tissue disruption, and support better clinical workflows. Its headquarters were in San Diego, California, and it maintained an international commercial footprint beyond the United States. NuVasive’s business model centered on spine implants, surgical instruments, biologics-related offerings, and enabling technologies used in complex spinal procedures. In addition to hardware, the company emphasized surgeon education, training programs, and clinical support services. That mix of products and services helped differentiate NuVasive in a highly competitive orthopedic and spine market where adoption depends on surgeon preference, clinical evidence, hospital economics, and technology integration. Its main competitive set included large medtech names active in spine such as Globus Medical, Medtronic, and Stryker. From a historical perspective, NuVasive emerged as a specialist in less-invasive spine surgery and gradually broadened its portfolio to address a wider range of spinal pathologies and procedure types. The company’s strategy was to combine innovation with a strong procedural ecosystem, aiming to become a leading spine technology platform. It also developed a broader geographic presence, serving the U.S. market while expanding internationally through distributor relationships and surgeon-engagement programs, including activity in Asia-Pacific. The key recent development is corporate integration rather than standalone operating growth. In February 2023, NuVasive agreed to combine with Globus Medical in an all-stock merger. The transaction closed on September 1, 2023, and NuVasive common stock ceased trading on the NASDAQ at the close of trading on August 31, 2023. As a result, NuVasive no longer exists as an independent listed equity; it became a wholly owned subsidiary of Globus Medical. For investors, that means NUVA is now primarily relevant for historical analysis, legacy filings, and understanding the evolution of the U.S. spine device industry. For SEO and market-context purposes, NuVasive should therefore be described as a former NASDAQ-listed U.S. medtech company in the Health & Pharma sector, with a legacy franchise in spine surgery, minimally invasive procedures, surgeon education, and international commercialization, now absorbed into Globus Medical.